Telix Pharmaceuticals | TLX - Ebitda



金融业
股票价格
AUD
资产
AUD 1.36B
现金及等价物
AUD 141.87M
销售成本
AUD 245.71M
流动资产
AUD 488.02M
流动负债
AUD 242.34M
债务
AUD 467.11M
EBIT
AUD 46.36M
EBITDA
AUD 76.49M
EPS每股收益
AUD 0.1
股本和储备
AUD 408.17M
销售毛利
AUD 260.35M
债务利息支出
AUD 19.39M
利息收入
AUD 1.37M
贷款资金
AUD 564.44M
市值
AUD 4.95B
净收入
AUD 38.33M
营业费用
AUD 430.99M
营业利润
AUD 46.36M
普通股股本
AUD 339.79M
PE价格收益
223.36
税前利润
AUD 76.73M
销售收入
AUD 477.35M
销售和管理费用
AUD 107.02M
股票
AUD 37.08M
贸易债权人
AUD 168.97M
应收帐款人
AUD 170.39M


Ebitda 更改 日
Cochlear AUD 306.4M 13.5M 2025-12
CSL USD 3.13B 1.17B 2025-12
Integral Diagnostics AUD 46.27M 3.52M 2024-06
Mayne Pharma AUD 20.9M 5.2M 2025-06
Medical Developments International AUD 1.78M 3.78M 2024-12
Mesoblast USD -17.08M 3.21M 2026-06
Neuren Pharmaceuticals AUD 11.14M 165.56M 2025-12
Pacific Edge NZD -13.97M 332K 2024-09
Paradigm Biopharmaceuticals AUD -5.86M 3.79M 2024-12
Polynovo AUD 3.89M 100K 2025-12
PYC Therapeutics AUD -22.79M 1.5M 2025-12
Ramsay Health Care AUD 1.12B 10.6M 2025-12
ResMed USD 568.84M 21.36M 2026-03
Sonic Healthcare AUD 839.07M 51.09M 2024-12